Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 492

1.

Template for the description of cell-based toxicological test methods to allow evaluation and regulatory use of the data.

Krebs A, Waldmann T, Wilks MF, Van Vugt-Lussenburg BMA, Van der Burg B, Terron A, Steger-Hartmann T, Ruegg J, Rovida C, Pedersen E, Pallocca G, Luijten M, Leite SB, Kustermann S, Kamp H, Hoeng J, Hewitt P, Herzler M, Hengstler JG, Heinonen T, Hartung T, Hardy B, Gantner F, Fritsche E, Fant K, Ezendam J, Exner T, Dunkern T, Dietrich DR, Coecke S, Busquet F, Braeuning A, Bondarenko O, Bennekou SH, Beilmann M, Leist M.

ALTEX. 2019;36(4):682-699. doi: 10.14573/altex.1909271.

2.

The effect of chronic vitamin deficiency and long term very low dose exposure to 6 pesticides mixture on neurological outcomes - A real-life risk simulation approach.

Tsatsakis A, Tyshko NV, Docea AO, Shestakova SI, Sidorova YS, Petrov NA, Zlatian O, Mach M, Hartung T, Tutelyan VA.

Toxicol Lett. 2019 Oct 15;315:96-106. doi: 10.1016/j.toxlet.2019.07.026. Epub 2019 Aug 3.

PMID:
31386889
3.

Long-term effects of chromium on morphological and immunological parameters of Wistar rats.

Karaulov AV, Renieri EA, Smolyagin AI, Mikhaylova IV, Stadnikov AA, Begun DN, Tsarouhas K, Buha Djordjevic A, Hartung T, Tsatsakis A.

Food Chem Toxicol. 2019 Nov;133:110748. doi: 10.1016/j.fct.2019.110748. Epub 2019 Aug 1.

PMID:
31377140
4.

Frequency and network analysis of depressive symptoms in patients with cancer compared to the general population.

Hartung TJ, Fried EI, Mehnert A, Hinz A, Vehling S.

J Affect Disord. 2019 Sep 1;256:295-301. doi: 10.1016/j.jad.2019.06.009. Epub 2019 Jun 4.

PMID:
31200167
5.

Adaptation of the Systematic Review Framework to the Assessment of Toxicological Test Methods: Challenges and Lessons Learned with the Zebrafish Embryotoxicity Test.

Stephens ML, Akgün-Ölmez SG, Hoffmann S, de Vries R, Flick B, Hartung T, Lalu M, Maertens A, Witters H, Wright R, Tsaioun K.

Toxicol Sci. 2018 Jun 13. pii: kfz128. doi: 10.1093/toxsci/kfz128. [Epub ahead of print]

6.

Suitability of 3D human brain spheroid models to distinguish toxic effects of gold and poly-lactic acid nanoparticles to assess biocompatibility for brain drug delivery.

Leite PEC, Pereira MR, Harris G, Pamies D, Dos Santos LMG, Granjeiro JM, Hogberg HT, Hartung T, Smirnova L.

Part Fibre Toxicol. 2019 Jun 3;16(1):22. doi: 10.1186/s12989-019-0307-3.

7.

Corrigendum to Stage-specific metabolic features of differentiating neurons: Implications for toxicant sensitivity Toxicol Appl Pharmacol, 354 (2018) 64-80.

Delp J, Gutbier S, Cerff M, Zasada C, Niedenführ S, Zhao L, Smirnova L, Hartung T, Borlinghaus H, Schreiber F, Bergemann J, Gätgens J, Beyss M, Azzouzi S, Waldmann T, Kempa S, Nöh K, Leist M.

Toxicol Appl Pharmacol. 2019 Jun 1;372:70. doi: 10.1016/j.taap.2019.04.010. Epub 2019 Apr 16. No abstract available.

PMID:
31002859
8.

Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer.

Nguyen T, Kirsch BJ, Asaka R, Nabi K, Quinones A, Tan J, Antonio MJ, Camelo F, Li T, Nguyen S, Hoang G, Nguyen K, Udupa S, Sazeides C, Shen YA, Elgogary A, Reyes J, Zhao L, Kleensang A, Chaichana KL, Hartung T, Betenbaugh MJ, Marie SK, Jung JG, Wang TL, Gabrielson E, Le A.

Cell Rep. 2019 Apr 9;27(2):491-501.e6. doi: 10.1016/j.celrep.2019.03.036.

9.

Nonanimal Models for Acute Toxicity Evaluations: Applying Data-Driven Profiling and Read-Across.

Russo DP, Strickland J, Karmaus AL, Wang W, Shende S, Hartung T, Aleksunes LM, Zhu H.

Environ Health Perspect. 2019 Apr;127(4):47001. doi: 10.1289/EHP3614.

10.

Towards quality assurance and quality control in untargeted metabolomics studies.

Beger RD, Dunn WB, Bandukwala A, Bethan B, Broadhurst D, Clish CB, Dasari S, Derr L, Evans A, Fischer S, Flynn T, Hartung T, Herrington D, Higashi R, Hsu PC, Jones C, Kachman M, Karuso H, Kruppa G, Lippa K, Maruvada P, Mosley J, Ntai I, O'Donovan C, Playdon M, Raftery D, Shaughnessy D, Souza A, Spaeder T, Spalholz B, Tayyari F, Ubhi B, Verma M, Walk T, Wilson I, Witkin K, Bearden DW, Zanetti KA.

Metabolomics. 2019 Jan 3;15(1):4. doi: 10.1007/s11306-018-1460-7.

PMID:
30830465
11.

[Psychosocial Care For Patients With Amyotrophic Lateral Sclerosis: A Narrative Review].

Esser P, Metelmann M, Hartung T, Claßen J, Mehnert A, Koranyi S.

Psychother Psychosom Med Psychol. 2019 Oct;69(9-10):372-381. doi: 10.1055/a-0806-7862. Epub 2019 Feb 7. German.

PMID:
30731512
12.

A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine.

Plummer S, Wallace S, Ball G, Lloyd R, Schiapparelli P, Quiñones-Hinojosa A, Hartung T, Pamies D.

Sci Rep. 2019 Feb 5;9(1):1407. doi: 10.1038/s41598-018-38130-0.

13.

Educational level and the risk of depression after prostate cancer.

Friberg AS, Rask Moustsen I, Benzon Larsen S, Hartung T, Wreford Andersen E, Halgren Olsen M, Tjønneland A, Kjaer SK, Johansen C, Brasso K, Oksbjerg Dalton S.

Acta Oncol. 2019 May;58(5):722-729. doi: 10.1080/0284186X.2019.1566773. Epub 2019 Jan 30.

PMID:
30700197
14.

Toward Good In Vitro Reporting Standards.

Hartung T, De Vries R, Hoffmann S, Hogberg HT, Smirnova L, Tsaioun K, Whaley P, Leist M.

ALTEX. 2019;36(1):3-17. doi: 10.14573/altex.1812191.

15.

Microglia Increase Inflammatory Responses in iPSC-Derived Human BrainSpheres.

Abreu CM, Gama L, Krasemann S, Chesnut M, Odwin-Dacosta S, Hogberg HT, Hartung T, Pamies D.

Front Microbiol. 2018 Dec 4;9:2766. doi: 10.3389/fmicb.2018.02766. eCollection 2018.

16.

Optimizing drug discovery by Investigative Toxicology: Current and future trends.

Beilmann M, Boonen H, Czich A, Dear G, Hewitt P, Mow T, Newham P, Oinonen T, Pognan F, Roth A, Valentin JP, Van Goethem F, Weaver RJ, Birk B, Boyer S, Caloni F, Chen AE, Corvi R, Cronin MTD, Daneshian M, Ewart LC, Fitzgerald RE, Hamilton GA, Hartung T, Kangas JD, Kramer NI, Leist M, Marx U, Polak S, Rovida C, Testai E, Van der Water B, Vulto P, Steger-Hartmann T.

ALTEX. 2019;36(2):289-313. doi: 10.14573/altex.1808181. Epub 2018 Dec 20.

17.

Missing the Difference Between Big Data and Artificial Intelligence in RASAR Versus Traditional QSAR.

Luechtefeld T, Marsh D, Hartung T.

Toxicol Sci. 2019 Jan 1;167(1):4-5. doi: 10.1093/toxsci/kfy287. No abstract available.

PMID:
30500944
18.

Weighted Gene Correlation Network Analysis (WGCNA) Reveals Novel Transcription Factors Associated With Bisphenol A Dose-Response.

Maertens A, Tran V, Kleensang A, Hartung T.

Front Genet. 2018 Nov 12;9:508. doi: 10.3389/fgene.2018.00508. eCollection 2018.

19.

Return to Work in Patients with Hematological Cancers 1 Year after Treatment: A Prospective Longitudinal Study.

Hartung TJ, Sautier LP, Scherwath A, Sturm K, Kröger N, Koch U, Mehnert A.

Oncol Res Treat. 2018;41(11):697-701. doi: 10.1159/000491589. Epub 2018 Oct 13.

20.

Big-data and machine learning to revamp computational toxicology and its use in risk assessment.

Luechtefeld T, Rowlands C, Hartung T.

Toxicol Res (Camb). 2018 May 1;7(5):732-744. doi: 10.1039/c8tx00051d. eCollection 2018 Sep 1. Review.

21.

Regulatory acceptance of read-across.

Chesnut M, Yamada T, Adams T, Knight D, Kleinstreuer N, Kass G, Luechtefeld T, Hartung T.

ALTEX. 2018;35(3):413-419. doi: 10.14573/altex.1805081. No abstract available.

22.

Animal testing and its alternatives - the most important omics is economics.

Meigs L, Smirnova L, Rovida C, Leist M, Hartung T.

ALTEX. 2018;35(3):275-305. doi: 10.14573/altex.1807041.

23.

Machine Learning of Toxicological Big Data Enables Read-Across Structure Activity Relationships (RASAR) Outperforming Animal Test Reproducibility.

Luechtefeld T, Marsh D, Rowlands C, Hartung T.

Toxicol Sci. 2018 Sep 1;165(1):198-212. doi: 10.1093/toxsci/kfy152.

24.

Toxicity, recovery, and resilience in a 3D dopaminergic neuronal in vitro model exposed to rotenone.

Harris G, Eschment M, Orozco SP, McCaffery JM, Maclennan R, Severin D, Leist M, Kleensang A, Pamies D, Maertens A, Hogberg HT, Freeman D, Kirkwood A, Hartung T, Smirnova L.

Arch Toxicol. 2018 Aug;92(8):2587-2606. doi: 10.1007/s00204-018-2250-8. Epub 2018 Jun 28.

25.

Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems.

Pamies D, Bal-Price A, Chesné C, Coecke S, Dinnyes A, Eskes C, Grillari R, Gstraunthaler G, Hartung T, Jennings P, Leist M, Martin U, Passier R, Schwamborn JC, Stacey GN, Ellinger-Ziegelbauer H, Daneshian M.

ALTEX. 2018;35(3):353-378. doi: 10.14573/altex.1710081. Epub 2018 Apr 13.

26.

3S - Systematic, systemic, and systems biology and toxicology.

Smirnova L, Kleinstreuer N, Corvi R, Levchenko A, Fitzpatrick SC, Hartung T.

ALTEX. 2018;35(2):139-162. doi: 10.14573/altex.1804051.

27.

Induction of IL-10-balanced immune profiles following exposure to LTA from Staphylococcus epidermidis.

Volz T, Kaesler S, Draing C, Hartung T, Röcken M, Skabytska Y, Biedermann T.

Exp Dermatol. 2018 Apr;27(4):318-326. doi: 10.1111/exd.13540.

PMID:
29569765
28.

The Generalized Anxiety Disorder Screener (GAD-7) and the anxiety module of the Hospital and Depression Scale (HADS-A) as screening tools for generalized anxiety disorder among cancer patients.

Esser P, Hartung TJ, Friedrich M, Johansen C, Wittchen HU, Faller H, Koch U, Härter M, Keller M, Schulz H, Wegscheider K, Weis J, Mehnert A.

Psychooncology. 2018 Jun;27(6):1509-1516. doi: 10.1002/pon.4681. Epub 2018 Mar 30.

PMID:
29473255
29.

Rotenone exerts developmental neurotoxicity in a human brain spheroid model.

Pamies D, Block K, Lau P, Gribaldo L, Pardo CA, Barreras P, Smirnova L, Wiersma D, Zhao L, Harris G, Hartung T, Hogberg HT.

Toxicol Appl Pharmacol. 2018 Sep 1;354:101-114. doi: 10.1016/j.taap.2018.02.003. Epub 2018 Feb 8.

30.
31.

Stage-specific metabolic features of differentiating neurons: Implications for toxicant sensitivity.

Delp J, Gutbier S, Cerff M, Zasada C, Niedenführ S, Zhao L, Smirnova L, Hartung T, Borlinghaus H, Schreiber F, Bergemann J, Gätgens J, Beyss M, Azzouzi S, Waldmann T, Kempa S, Nöh K, Leist M.

Toxicol Appl Pharmacol. 2018 Sep 1;354:64-80. doi: 10.1016/j.taap.2017.12.013. Epub 2017 Dec 24. Erratum in: Toxicol Appl Pharmacol. 2019 Jun 1;372:70.

PMID:
29278688
32.

Green Toxicology-Know Early About and Avoid Toxic Product Liabilities.

Maertens A, Hartung T.

Toxicol Sci. 2018 Feb 1;161(2):285-289. doi: 10.1093/toxsci/kfx243. Review.

PMID:
29267930
33.

Computational approaches to chemical hazard assessment.

Luechtefeld T, Hartung T.

ALTEX. 2017;34(4):459-478. doi: 10.14573/altex.1710141.

34.

Adverse outcome pathways: opportunities, limitations and open questions.

Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Bennekou SH, Limonciel A, Vinken M, Schildknecht S, Waldmann T, Danen E, van Ravenzwaay B, Kamp H, Gardner I, Godoy P, Bois FY, Braeuning A, Reif R, Oesch F, Drasdo D, Höhme S, Schwarz M, Hartung T, Braunbeck T, Beltman J, Vrieling H, Sanz F, Forsby A, Gadaleta D, Fisher C, Kelm J, Fluri D, Ecker G, Zdrazil B, Terron A, Jennings P, van der Burg B, Dooley S, Meijer AH, Willighagen E, Martens M, Evelo C, Mombelli E, Taboureau O, Mantovani A, Hardy B, Koch B, Escher S, van Thriel C, Cadenas C, Kroese D, van de Water B, Hengstler JG.

Arch Toxicol. 2017 Nov;91(11):3477-3505. doi: 10.1007/s00204-017-2045-3. Epub 2017 Oct 19. Review.

PMID:
29051992
35.

Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells.

Ramirez T, Strigun A, Verlohner A, Huener HA, Peter E, Herold M, Bordag N, Mellert W, Walk T, Spitzer M, Jiang X, Sperber S, Hofmann T, Hartung T, Kamp H, van Ravenzwaay B.

Arch Toxicol. 2018 Feb;92(2):893-906. doi: 10.1007/s00204-017-2079-6. Epub 2017 Sep 30.

36.

Improving the human-robot interface for telemanipulated robotic long bone fracture reduction: Joystick device vs. haptic manipulator.

Suero EM, Hartung T, Westphal R, Hawi N, Liodakis E, Citak M, Krettek C, Stuebig T.

Int J Med Robot. 2018 Feb;14(1). doi: 10.1002/rcs.1863. Epub 2017 Sep 25.

PMID:
28948678
37.

COMSKIL Communication Training in Oncology-Adaptation to German Cancer Care Settings.

Hartung TJ, Kissane D, Mehnert A.

Recent Results Cancer Res. 2018;210:191-205. doi: 10.1007/978-3-319-64310-6_12.

PMID:
28924687
38.

Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform.

Skardal A, Murphy SV, Devarasetty M, Mead I, Kang HW, Seol YJ, Shrike Zhang Y, Shin SR, Zhao L, Aleman J, Hall AR, Shupe TD, Kleensang A, Dokmeci MR, Jin Lee S, Jackson JD, Yoo JJ, Hartung T, Khademhosseini A, Soker S, Bishop CE, Atala A.

Sci Rep. 2017 Aug 18;7(1):8837. doi: 10.1038/s41598-017-08879-x.

39.

3D Differentiation of LUHMES Cell Line to Study Recovery and Delayed Neurotoxic Effects.

Harris G, Hogberg H, Hartung T, Smirnova L.

Curr Protoc Toxicol. 2017 Aug 4;73:11.23.1-11.23.28. doi: 10.1002/cptx.29.

40.

A Novel Selective Inverse Agonist of the CB2 Receptor as a Radiolabeled Tool Compound for Kinetic Binding Studies.

Martella A, Sijben H, Rufer AC, Grether U, Fingerle J, Ullmer C, Hartung T, IJzerman AP, van der Stelt M, Heitman LH.

Mol Pharmacol. 2017 Oct;92(4):389-400. doi: 10.1124/mol.117.108605. Epub 2017 Jul 26.

PMID:
28747489
41.
42.

Loss of Hepatic Mitochondrial Long-Chain Fatty Acid Oxidation Confers Resistance to Diet-Induced Obesity and Glucose Intolerance.

Lee J, Choi J, Selen Alpergin ES, Zhao L, Hartung T, Scafidi S, Riddle RC, Wolfgang MJ.

Cell Rep. 2017 Jul 18;20(3):655-667. doi: 10.1016/j.celrep.2017.06.080.

43.

Food for thought ... the first ten years.

Hartung T.

ALTEX. 2017;34(2):187-192. doi: 10.14573/altex.1703311. No abstract available.

PMID:
28668969
44.

Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography.

Gobbi LC, Knust H, Körner M, Honer M, Czech C, Belli S, Muri D, Edelmann MR, Hartung T, Erbsmehl I, Grall-Ulsemer S, Koblet A, Rueher M, Steiner S, Ravert HT, Mathews WB, Holt DP, Kuwabara H, Valentine H, Dannals RF, Wong DF, Borroni E.

J Med Chem. 2017 Sep 14;60(17):7350-7370. doi: 10.1021/acs.jmedchem.7b00632. Epub 2017 Jul 12.

PMID:
28654263
45.

The Hospital Anxiety and Depression Scale (HADS) and the 9-item Patient Health Questionnaire (PHQ-9) as screening instruments for depression in patients with cancer.

Hartung TJ, Friedrich M, Johansen C, Wittchen HU, Faller H, Koch U, Brähler E, Härter M, Keller M, Schulz H, Wegscheider K, Weis J, Mehnert A.

Cancer. 2017 Nov 1;123(21):4236-4243. doi: 10.1002/cncr.30846. Epub 2017 Jun 27.

46.

The Threshold of Toxicological Concern for prenatal developmental toxicity in rats and rabbits.

van Ravenzwaay B, Jiang X, Luechtefeld T, Hartung T.

Regul Toxicol Pharmacol. 2017 Aug;88:157-172. doi: 10.1016/j.yrtph.2017.06.008. Epub 2017 Jun 20.

47.

One in two cancer patients is significantly distressed: Prevalence and indicators of distress.

Mehnert A, Hartung TJ, Friedrich M, Vehling S, Brähler E, Härter M, Keller M, Schulz H, Wegscheider K, Weis J, Koch U, Faller H.

Psychooncology. 2018 Jan;27(1):75-82. doi: 10.1002/pon.4464. Epub 2017 Jun 16.

PMID:
28568377
48.

From in vivo to in vitro: The medical device testing paradigm shift.

Kerecman Myers D, Goldberg AM, Poth A, Wolf MF, Carraway J, McKim J, Coleman KP, Hutchinson R, Brown R, Krug HF, Bahinski A, Hartung T.

ALTEX. 2017;34(4):479-500. doi: 10.14573/altex.1608081. Epub 2017 May 25.

49.

A primer on systematic reviews in toxicology.

Hoffmann S, de Vries RBM, Stephens ML, Beck NB, Dirven HAAM, Fowle JR 3rd, Goodman JE, Hartung T, Kimber I, Lalu MM, Thayer K, Whaley P, Wikoff D, Tsaioun K.

Arch Toxicol. 2017 Jul;91(7):2551-2575. doi: 10.1007/s00204-017-1980-3. Epub 2017 May 13. Review.

50.

The Mammalian Malonyl-CoA Synthetase ACSF3 Is Required for Mitochondrial Protein Malonylation and Metabolic Efficiency.

Bowman CE, Rodriguez S, Selen Alpergin ES, Acoba MG, Zhao L, Hartung T, Claypool SM, Watkins PA, Wolfgang MJ.

Cell Chem Biol. 2017 Jun 22;24(6):673-684.e4. doi: 10.1016/j.chembiol.2017.04.009. Epub 2017 May 4.

Supplemental Content

Loading ...
Support Center